Abstract
Mutations in mitochondrial genes, oxidative insults, imbalance in redox mechanisms and dysregulated mitophagy are some of the leading causes for mitochondrial dysfunction and subsequent neurodegeneration in Parkinson’s disease. Targeting mitochondrial dysfunction and prolonging neuronal survival could potentially prove to be useful neuroprotective strategies. In some recent investigations, peroxisome proliferator activated receptor gamma coactivator 1 alpha mediated mitochondrial biogenesis and its ability to restore reactive oxygen species-detoxifying enzymes have been observed in preclinical studies. In this review, we discuss about physiological importance of peroxisome proliferator activated receptor gamma coactivator 1 alpha along with a list of its activators that could prove useful as possible neuroprotectants in Parkinson’s disease.
Keywords: Mitochondrial biogenesis, Mitochondrial transcription factor A, Neurodegeneration, Parkinson’s disease, Reactive oxygen species, Sirtuin 1.
CNS & Neurological Disorders - Drug Targets
Title:Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson’s Disease
Volume: 14 Issue: 8
Author(s): Nihar Ranjan Das and Shyam Sunder Sharma
Affiliation:
Keywords: Mitochondrial biogenesis, Mitochondrial transcription factor A, Neurodegeneration, Parkinson’s disease, Reactive oxygen species, Sirtuin 1.
Abstract: Mutations in mitochondrial genes, oxidative insults, imbalance in redox mechanisms and dysregulated mitophagy are some of the leading causes for mitochondrial dysfunction and subsequent neurodegeneration in Parkinson’s disease. Targeting mitochondrial dysfunction and prolonging neuronal survival could potentially prove to be useful neuroprotective strategies. In some recent investigations, peroxisome proliferator activated receptor gamma coactivator 1 alpha mediated mitochondrial biogenesis and its ability to restore reactive oxygen species-detoxifying enzymes have been observed in preclinical studies. In this review, we discuss about physiological importance of peroxisome proliferator activated receptor gamma coactivator 1 alpha along with a list of its activators that could prove useful as possible neuroprotectants in Parkinson’s disease.
Export Options
About this article
Cite this article as:
Das Ranjan Nihar and Sharma Sunder Shyam, Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson’s Disease, CNS & Neurological Disorders - Drug Targets 2015; 14 (8) . https://dx.doi.org/10.2174/1871527314666150326000018
DOI https://dx.doi.org/10.2174/1871527314666150326000018 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimers Disease
Current Medicinal Chemistry The Effect of Different microRNA Backbones on Artificial miRNA Expression and Knockdown Activity Against HIV-1 Replication
MicroRNA Mechanisms of Prion Protein Aggregation
Protein & Peptide Letters Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids
Current Neuropharmacology A Novel Monoclonal Antibody Against the C-terminus of β-Tubulin Recognizes Endocytic Organelles in Trypanosoma cruzi
Protein & Peptide Letters Andrographolide Mitigates Unfolded Protein Response Pathway and Apoptosis Involved in Chikungunya Virus Infection
Combinatorial Chemistry & High Throughput Screening Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry Insights into Immunophilin Structure and Function
Current Medicinal Chemistry β-Galactosylated Alkyl-oligoamine Derivatives of Polyethylenimine Enhanced pDNA Delivery into Hepatic Cells with Reduced Toxicity
Current Nanoscience Antitumoral Potential of Snake Venom Phospholipases A2 and Synthetic Peptides
Current Pharmaceutical Biotechnology Ubiquitin-Proteasome Pathway Components as Therapeutic Targets for CNS Maladies
Current Pharmaceutical Design Early Development of Sea Urchin P.lividus Under Static (6 mT) and Pulsed Magnetic Fields (15 and 72 Hz)
Current Chemical Biology Pre-feasibility Study for Establishing Radioisotope and Radiopharmaceutical Production Facilities in Developing Countries
Current Radiopharmaceuticals A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Biomarkers
Current Pharmaceutical Design Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy
Current Cancer Drug Targets Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity
Current Cancer Drug Targets Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers
Current Pharmaceutical Design Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design